Search Results

Hands tearing money over red background. Professional challenges, disagreement, greed. Contemporary art collage. Concept of financial literacy, economic, business, money

Layoffs

Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review of potential strategic alternatives and options for the business.

May 9, 2025

·

2 min read

·

Tristan Manalac

Layoffs

IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.

January 10, 2025

·

1 min read

·

Angela Gabriel

Business

IGM Biosciences Announces Refocusing of Sanofi Collaboration

IGM Biosciences, Inc. today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.

April 17, 2024

·

4 min read

Press Releases

Lyme IgM and IgG ImmunoBlots Receive FDA Clearance

July 3, 2025

·

2 min read

Business

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.

May 8, 2024

·

9 min read

Business

IGM Biosciences Announces Third Quarter 2023 Financial Results

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.

November 13, 2023

·

9 min read

Biotech Bay

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

IGM Biosciences, Inc. announced that it will focus its resources in two strategic areas: treating colorectal cancer using IgM death receptor 5 agonist antibodies, and treating autoimmune diseases using IgM T cell engager antibodies.

December 5, 2023

·

7 min read

Biotech Bay

IGM Biosciences to Present at the 2024 Jefferies Healthcare Conference

IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.

May 29, 2024

·

1 min read

Biotech Bay

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT.

April 10, 2024

·

1 min read

Business

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

March 7, 2024

·

9 min read